bluebird bio (BLUE) Given News Sentiment Rating of 0.22

News headlines about bluebird bio (NASDAQ:BLUE) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. bluebird bio earned a media sentiment score of 0.22 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 48.6024786959736 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

These are some of the media headlines that may have effected Accern’s scoring:

bluebird bio opened at $181.25 on Tuesday, MarketBeat reports. The stock has a market capitalization of $9.21 billion, a P/E ratio of -23.51 and a beta of 2.17. bluebird bio has a 52 week low of $74.45 and a 52 week high of $236.17.

bluebird bio (NASDAQ:BLUE) last posted its quarterly earnings results on Monday, May 7th. The biotechnology company reported ($2.31) EPS for the quarter, missing the Zacks’ consensus estimate of ($2.01) by ($0.30). The company had revenue of $15.96 million during the quarter, compared to analyst estimates of $5.85 million. bluebird bio had a negative net margin of 857.55% and a negative return on equity of 27.61%. The firm’s revenue for the quarter was up 133.7% compared to the same quarter last year. During the same period last year, the firm earned ($1.68) EPS. equities analysts expect that bluebird bio will post -9.33 EPS for the current year.

A number of research firms have recently weighed in on BLUE. Cantor Fitzgerald reissued an “underweight” rating on shares of bluebird bio in a report on Wednesday, May 16th. Sanford C. Bernstein reissued a “market perform” rating and set a $211.00 target price on shares of bluebird bio in a report on Monday, May 7th. Maxim Group set a $200.00 target price on bluebird bio and gave the stock a “hold” rating in a report on Thursday, May 3rd. BMO Capital Markets dropped their target price on bluebird bio from $222.00 to $216.00 and set a “buy” rating for the company in a report on Thursday, May 3rd. Finally, BTIG Research reissued a “buy” rating on shares of bluebird bio in a report on Thursday, May 3rd. Four analysts have rated the stock with a sell rating, nine have assigned a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $195.80.

In related news, Director Mark Vachon sold 6,000 shares of the business’s stock in a transaction dated Thursday, March 15th. The stock was sold at an average price of $214.38, for a total value of $1,286,280.00. Following the completion of the transaction, the director now owns 7,000 shares of the company’s stock, valued at $1,500,660. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider David Davidson sold 13,000 shares of the business’s stock in a transaction dated Wednesday, May 2nd. The shares were sold at an average price of $177.52, for a total value of $2,307,760.00. Following the completion of the transaction, the insider now directly owns 37,905 shares of the company’s stock, valued at approximately $6,728,895.60. The disclosure for this sale can be found here. In the last ninety days, insiders sold 46,250 shares of company stock valued at $8,269,990. 3.00% of the stock is owned by insiders.

bluebird bio Company Profile

bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in various clinical studies for the treatment of transfusion- transfusion-dependent ß-thalassemia and severe sickle cell disease.

Insider Buying and Selling by Quarter for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.




Leave a Reply